Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record.

High dose probiotic and prebiotic cotherapy for remission induction of active Crohn’s disease

Fujimori, Shunji, Tatsuguchi, Atsushi, Gudis, Katya, Kishida, Teruyuki, Mitsui, Keigo, Ehara, Akihito, Kobayashi, Tsuyoshi, Sekita, Yoshihisa, Seo, Tsuguhiko, Sakamoto, Choitsu·2007·Journal of Gastroenterology and Hepatology

Abstract

Background: Clinical trials of probiotic treatment for Crohn’s disease (CD) have yielded conflicting results. This study assessed the clinical usefulness of combined probiotic and prebiotic therapy in the treatment of active CD. Method: Ten active CD outpatients without history of operation for CD were enrolled. Their mean (±SD) age was 27 ± 7 years and the main symptoms presented were diarrhea and abdominal pain. Patients’ initial therapeutic regimen of aminosalicylates and prednisolone failed to achieve remission. Patients were thus initiated on a synbiotic therapy, consisting of both probiotics (75 billion colony forming units [CFU] daily) and prebiotics (psyllium 9.9 g daily). Probiotics mainly comprised Bifidobacterium and Lactobacillus. Patients were free to adjust their intake of probiotics or prebiotics throughout the trial. Crohn’s disease activity index (CDAI), International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score and blood sample variables were evaluated and compared before and after the trial. Results: The duration of the trial was 13.0 ± 4.5 months. By the end of therapy, each patient had taken a 45 ± 24 billion CFU daily probiotic dose, with six patients taking an additional 7.9 ± 3.6 g daily psyllium dose. Seven patients had improved clinical symptoms following combined probiotic and prebiotic therapy. Both CDAI and IOIBD scores were significantly reduced after therapy (255–136, P = 0.009; 3.5–2.1, P = 0.03, respectively). Six patients had a complete response, one had a partial response, and three were non‐responders. Two patients were able to discontinue their prednisolone therapy, while four patients decreased their intake. There were no adverse events. Conclusion: High‐dose probiotic and prebiotic cotherapy can be safely and effectively used for the treatment of active CD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1746.2006.04535.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 177

Metadata

Authors
Fujimori, S., Tatsuguchi, A., Gudis, K., Kishida, T., Mitsui, K., Ehara, A., Kobayashi, T., Sekita, Y., Seo, T., & Sakamoto, C.
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2007-08
Volume
22
Issue
8
Pages
1199-1204
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W1975092923
Cited by
177
References
0
FWCI
4.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High dose probiotic and prebiotic cotherapy for remission induction of active Crohn’s disease. https://app.cochat.ai/papers/10.1111/j.1440-1746.2006.04535.x
The paper
Fujimori, S., Tatsuguchi, A., Gudis, K., Kishida, T., Mitsui, K., Ehara, A., Kobayashi, T., Sekita, Y., Seo, T., & Sakamoto, C. (2007). High dose probiotic and prebiotic cotherapy for remission induction of active Crohn’s disease. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.2006.04535.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.